Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Neuroendocrine Tumor Research Advances, and Viral Infectious Diseases and Gene Expression in Insects.
Baseline CT imaging parameters predicting overall and progression-free survival for patients with pulmonary metastases from soft tissue and bone sarcoma
ESR Essentials: imaging of lymphoma—practice recommendations by the European Society of Oncologic Imaging
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy
High Bacterial Abundances of <i>Dorea</i> and <i>Pediococcus</i> in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL
P04.01 Immunomonitoring of CD19. CAR T-cells in Large B-Cell Lymphoma- a two-center experience